Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy

Basit Öğe Kaydı
dc.authoridDas, Gitishree/0000-0002-5676-0768
dc.authoridGrozea, Ioana/0000-0002-2186-4364
dc.authoridBUTNARIU, Monica/0000-0002-2032-5000
dc.authoridSzopa, Agnieszka/0000-0002-6351-4047
dc.authoridPATRA, JAYANTA KUMAR/0000-0003-4118-4355
dc.authoridDisco Singh, Yengkhom/0000-0002-7580-2345
dc.authoridCalina, Daniela/0000-0002-1523-9116
dc.contributor.authorSharifi-Rad, Javad
dc.contributor.authorQuispe, Cristina
dc.contributor.authorPatra, Jayanta Kumar
dc.contributor.authorSingh, Yengkhom Disco
dc.contributor.authorPanda, Manasa Kumar
dc.contributor.authorDas, Gitishree
dc.contributor.authorAdetunji, Charles Oluwaseun
dc.date.accessioned2024-10-26T18:11:43Z
dc.date.available2024-10-26T18:11:43Z
dc.date.issued2021
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractPaclitaxel is a broad-spectrum anticancer compound, which was derived mainly from a medicinal plant, in particular, from the bark of the yew tree Taxus brevifolia Nutt. It is a representative of a class of diterpene taxanes, which are nowadays used as the most common chemotherapeutic agent against many forms of cancer. It possesses scientifically proven anticancer activity against, e.g., ovarian, lung, and breast cancers. The application of this compound is difficult because of limited solubility, recrystalization upon dilution, and cosolvent-induced toxicity. In these cases, nanotechnology and nanoparticles provide certain advantages such as increased drug half-life, lowered toxicity, and specific and selective delivery over free drugs. Nanodrugs possess the capability to buildup in the tissue which might be linked to enhanced permeability and retention as well as enhanced antitumour influence possessing minimal toxicity in normal tissues. This article presents information about paclitaxel, its chemical structure, formulations, mechanism of action, and toxicity. Attention is drawn on nanotechnology, the usefulness of nanoparticles containing paclitaxel, its opportunities, and also future perspective. This review article is aimed at summarizing the current state of continuous pharmaceutical development and employment of nanotechnology in the enhancement of the pharmacokinetic and pharmacodynamic features of paclitaxel as a chemotherapeutic agent.
dc.identifier.doi10.1155/2021/3687700
dc.identifier.issn1942-0900
dc.identifier.issn1942-0994
dc.identifier.pmid34707776
dc.identifier.scopus2-s2.0-85118573577
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1155/2021/3687700
dc.identifier.urihttps://hdl.handle.net/20.500.12418/30784
dc.identifier.volume2021
dc.identifier.wosWOS:000721503200011
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofOxidative Medicine and Cellular Longevity
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titlePaclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy
dc.typeReview Article

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu